Drug eluting stents versus PTA with GP IIb/IIIa blockade below the knee in patients with current ulcers--The BELOW Study.
J Cardiovasc Surg (Torino)
; 51(2): 203-12, 2010 Apr.
Article
en En
| MEDLINE
| ID: mdl-20354490
ABSTRACT
The study was designed as a feasibility trial to evaluate the use of GP IIb/IIIa blockade in connection with drug eluting stents, bare stents and PTA only. Sixty patients with current ulcers were randomly assigned to receive abciximab plus a sirolimus coated stent (N.=14), abciximab plus a bare stent (N.=16), abciximab plus PTA (N.=14) and PTA alone (N.=19). Angiographic control was performed at two and six months. Recanalization was successful in all cases. Two month restenosis rate was 9%, 45.5%, 67% and 46%. At six month follow-up restenosis rate was 9%, 67%, 75% and 58%, respectively; 14% of all patients had major amputations within six months. Adjunctive administration of abciximab during peripheral arterial intervention below the knee was found to be safe. Sirolimus coated stent administration was followed by a higher patency rate.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Fragmentos Fab de Inmunoglobulinas
/
Inhibidores de Agregación Plaquetaria
/
Fármacos Cardiovasculares
/
Stents
/
Angioplastia de Balón
/
Complejo GPIIb-IIIa de Glicoproteína Plaquetaria
/
Sirolimus
/
Extremidad Inferior
/
Stents Liberadores de Fármacos
/
Úlcera de la Pierna
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Observational_studies
Límite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Cardiovasc Surg (Torino)
Año:
2010
Tipo del documento:
Article
País de afiliación:
Alemania